NATCO PHARMA
Back to Income Statement
|
NATCO PHARMA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹1,885 Cr | ₹1,388 Cr | ₹715 Cr | ₹170 Cr | ₹441 Cr |
What is the latest Consolidated Net Profit of NATCO PHARMA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2025 | ₹1,885 Cr |
| Mar2024 | ₹1,388 Cr |
| Mar2023 | ₹715 Cr |
| Mar2022 | ₹170 Cr |
| Mar2021 | ₹441 Cr |
How is Consolidated Net Profit of NATCO PHARMA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,885 Cr | 35.81 | |
| Mar2024 | ₹1,388 Cr | 94.09 | |
| Mar2023 | ₹715 Cr | 320.76 | |
| Mar2022 | ₹170 Cr | -61.44 | |
| Mar2021 | ₹441 Cr | - | |
Compare Consolidated Net Profit of peers of NATCO PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NATCO PHARMA | ₹20,130.8 Cr | 2.2% | 14.2% | 24% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹436,859.0 Cr | 5.2% | 3.8% | -1.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹176,618.0 Cr | 2.2% | 11.3% | 7.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹144,718.0 Cr | 0.8% | 0.7% | 25.7% | Stock Analytics | |
| CIPLA | ₹107,722.0 Cr | 1.3% | 9.1% | -15.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹106,081.0 Cr | -3.5% | 2.7% | 10.3% | Stock Analytics | |
NATCO PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NATCO PHARMA | 2.2% |
14.2% |
24% |
| SENSEX | -0.4% |
7.1% |
-4% |
You may also like the below Video Courses